image
Healthcare - Medical - Devices - NASDAQ - US
$ 45.05
2.02 %
$ 1.82 B
Market Cap
-55.62
P/E
1. INTRINSIC VALUE

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc.[ Read More ]

The intrinsic value of one RXST stock under the base case scenario is HIDDEN Compared to the current market price of 45 USD, RxSight, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RXST

image
FINANCIALS
89.1 M REVENUE
81.77%
-50.1 M OPERATING INCOME
20.90%
-48.6 M NET INCOME
27.19%
-41.6 M OPERATING CASH FLOW
29.32%
-22.1 M INVESTING CASH FLOW
-55.39%
61.5 M FINANCING CASH FLOW
871.64%
45.4 M REVENUE
30.16%
-9.23 M OPERATING INCOME
-10.72%
-6.34 M NET INCOME
-4.26%
730 K OPERATING CASH FLOW
117.77%
-9.26 M INVESTING CASH FLOW
91.99%
878 K FINANCING CASH FLOW
-99.21%
Balance Sheet Decomposition RxSight, Inc.
image
Current Assets 168 M
Cash & Short-Term Investments 127 M
Receivables 20.3 M
Other Current Assets 20.9 M
Non-Current Assets 14.1 M
Long-Term Investments 711 K
PP&E 13.3 M
Other Non-Current Assets 147 K
Current Liabilities 20.9 M
Accounts Payable 3.86 M
Short-Term Debt 1.8 M
Other Current Liabilities 15.2 M
Non-Current Liabilities 1.28 M
Long-Term Debt 1.21 M
Other Non-Current Liabilities 74 K
EFFICIENCY
Earnings Waterfall RxSight, Inc.
image
Revenue 89.1 M
Cost Of Revenue 35.3 M
Gross Profit 53.8 M
Operating Expenses 104 M
Operating Income -50.1 M
Other Expenses -1.48 M
Net Income -48.6 M
RATIOS
60.36% GROSS MARGIN
60.36%
-56.23% OPERATING MARGIN
-56.23%
-54.57% NET MARGIN
-54.57%
-30.31% ROE
-30.31%
-26.63% ROA
-26.63%
-31.25% ROIC
-31.25%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis RxSight, Inc.
image
Net Income -48.6 M
Depreciation & Amortization 4.24 M
Capital Expenditures -4.81 M
Stock-Based Compensation 15.7 M
Change in Working Capital -9.07 M
Others -2.15 M
Free Cash Flow -46.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets RxSight, Inc.
image
Wall Street analysts predict an average 1-year price target for RXST of $67.8 , with forecasts ranging from a low of $42 to a high of $110 .
RXST Lowest Price Target Wall Street Target
42 USD -6.77%
RXST Average Price Target Wall Street Target
67.8 USD 50.50%
RXST Highest Price Target Wall Street Target
110 USD 144.17%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership RxSight, Inc.
image
Sold
0-3 MONTHS
3.62 M USD 2
3-6 MONTHS
2.34 M USD 3
6-9 MONTHS
5.84 M USD 3
9-12 MONTHS
47.4 M USD 9
Bought
1.01 M USD 1
0-3 MONTHS
305 K USD 1
3-6 MONTHS
205 K USD 1
6-9 MONTHS
202 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
5 days ago
Nov 12, 2024
Sell 61.4 K USD
Goldshleger Ilya
See remarks
- 1330
46.1325 USD
4 days ago
Nov 13, 2024
Bought 251 K USD
Corley Jesse Anderson
Director
+ 5570
45 USD
5 days ago
Nov 12, 2024
Bought 504 K USD
Corley Jesse Anderson
Director
+ 11111
45.3676 USD
4 days ago
Nov 13, 2024
Bought 75.9 K USD
Corley Jesse Anderson
Director
+ 1705
44.5 USD
4 days ago
Nov 13, 2024
Bought 184 K USD
Corley Jesse Anderson
Director
+ 4090
44.98 USD
1 week ago
Nov 07, 2024
Sell 159 K USD
Goldshleger Ilya
See remarks
- 2900
54.9616 USD
1 week ago
Nov 07, 2024
Sell 11.1 K USD
Goldshleger Ilya
See remarks
- 200
55.53 USD
1 week ago
Nov 04, 2024
Sell 145 K USD
Goldshleger Ilya
See remarks
- 2840
50.9843 USD
1 week ago
Nov 04, 2024
Sell 13.5 K USD
Goldshleger Ilya
See remarks
- 260
51.7372 USD
2 weeks ago
Oct 30, 2024
Sell 161 K USD
Goldshleger Ilya
See remarks
- 3105
51.9069 USD
3 weeks ago
Oct 25, 2024
Sell 154 K USD
Goldshleger Ilya
See remarks
- 3100
49.7937 USD
2 weeks ago
Oct 28, 2024
Sell 157 K USD
Goldshleger Ilya
See remarks
- 3100
50.643 USD
3 weeks ago
Oct 22, 2024
Sell 154 K USD
Goldshleger Ilya
See remarks
- 3100
49.6778 USD
4 weeks ago
Oct 18, 2024
Sell 150 K USD
Goldshleger Ilya
See remarks
- 3002
50.0745 USD
4 weeks ago
Oct 18, 2024
Sell 3.49 K USD
Goldshleger Ilya
See remarks
- 69
50.565 USD
4 weeks ago
Oct 18, 2024
Sell 1.72 K USD
Goldshleger Ilya
See remarks
- 34
50.59 USD
1 month ago
Oct 16, 2024
Sell 154 K USD
Goldshleger Ilya
See remarks
- 3100
49.7799 USD
1 month ago
Oct 14, 2024
Sell 155 K USD
Goldshleger Ilya
See remarks
- 3100
50.0865 USD
1 month ago
Oct 11, 2024
Sell 156 K USD
Goldshleger Ilya
See remarks
- 3100
50.1915 USD
1 month ago
Oct 10, 2024
Sell 152 K USD
Goldshleger Ilya
See remarks
- 3105
48.8231 USD
1 month ago
Oct 04, 2024
Sell 137 K USD
Goldshleger Ilya
See remarks
- 2866
47.9572 USD
1 month ago
Oct 04, 2024
Sell 1.36 K USD
Goldshleger Ilya
See remarks
- 28
48.47 USD
1 month ago
Oct 04, 2024
Sell 10 K USD
Goldshleger Ilya
See remarks
- 206
48.65 USD
1 month ago
Oct 08, 2024
Sell 150 K USD
Goldshleger Ilya
See remarks
- 3100
48.262 USD
1 month ago
Oct 01, 2024
Sell 249 K USD
Thunen Shelley B
See remarks
- 5201
47.9566 USD
1 month ago
Oct 01, 2024
Sell 464 K USD
Thunen Shelley B
See remarks
- 9521
48.6882 USD
1 month ago
Oct 01, 2024
Sell 13.7 K USD
Thunen Shelley B
See remarks
- 278
49.45 USD
1 month ago
Sep 30, 2024
Sell 80.4 K USD
Goldshleger Ilya
See remarks
- 1652
48.6919 USD
1 month ago
Sep 30, 2024
Sell 71.5 K USD
Goldshleger Ilya
See remarks
- 1448
49.3837 USD
1 month ago
Sep 26, 2024
Sell 153 K USD
Goldshleger Ilya
See remarks
- 3105
49.2926 USD
1 month ago
Sep 23, 2024
Sell 155 K USD
Goldshleger Ilya
See remarks
- 2950
52.6215 USD
1 month ago
Sep 23, 2024
Sell 8.03 K USD
Goldshleger Ilya
See remarks
- 150
53.53 USD
1 month ago
Sep 20, 2024
Sell 165 K USD
Goldshleger Ilya
See remarks
- 3100
53.1939 USD
2 months ago
Sep 17, 2024
Sell 174 K USD
Goldshleger Ilya
See remarks
- 3100
56.111 USD
3 months ago
Aug 05, 2024
Sell 44.4 K USD
Goldshleger Ilya
See remarks
- 1145
38.8011 USD
3 months ago
Aug 05, 2024
Sell 73.1 K USD
Goldshleger Ilya
See remarks
- 1855
39.4258 USD
3 months ago
Aug 05, 2024
Sell 42.2 K USD
Goldshleger Ilya
See remarks
- 1087
38.8289 USD
3 months ago
Aug 05, 2024
Sell 75.6 K USD
Goldshleger Ilya
See remarks
- 1913
39.5128 USD
3 months ago
Aug 05, 2024
Sell 71.3 K USD
Goldshleger Ilya
See remarks
- 1827
39.0429 USD
3 months ago
Aug 05, 2024
Sell 46.6 K USD
Goldshleger Ilya
See remarks
- 1173
39.7293 USD
4 months ago
Jul 01, 2024
Sell 476 K USD
Thunen Shelley B
Chief Financial Officer
- 8146
58.4072 USD
4 months ago
Jul 01, 2024
Sell 110 K USD
Thunen Shelley B
Chief Financial Officer
- 1854
59.477 USD
4 months ago
Jul 01, 2024
Sell 386 K USD
Thunen Shelley B
Chief Financial Officer
- 6599
58.5492 USD
4 months ago
Jul 01, 2024
Sell 107 K USD
Thunen Shelley B
Chief Financial Officer
- 1803
59.5641 USD
5 months ago
Jun 14, 2024
Sell 691 K USD
Andrews Julie
Director
- 11940
57.8399 USD
5 months ago
Jun 14, 2024
Sell 216 K USD
Andrews Julie
Director
- 3685
58.5291 USD
6 months ago
May 17, 2024
Bought 305 K USD
Tammenoms Bakker Juliet
Director
+ 5000
61.0913 USD
6 months ago
May 03, 2024
Sell 2.41 M USD
Kurtz Ronald M MD
President & CEO
- 40000
60.1468 USD
6 months ago
May 01, 2024
Sell 507 K USD
Thunen Shelley B
Chief Financial Officer
- 9620
52.6776 USD
6 months ago
May 01, 2024
Sell 20.2 K USD
Thunen Shelley B
Chief Financial Officer
- 380
53.0374 USD
7 months ago
Apr 01, 2024
Sell 441 K USD
Thunen Shelley B
Chief Financial Officer
- 8857
49.8145 USD
7 months ago
Apr 01, 2024
Sell 40.2 K USD
Thunen Shelley B
Chief Financial Officer
- 800
50.2725 USD
7 months ago
Apr 01, 2024
Sell 445 K USD
Thunen Shelley B
Chief Financial Officer
- 8938
49.8126 USD
7 months ago
Apr 01, 2024
Sell 33.3 K USD
Thunen Shelley B
Chief Financial Officer
- 662
50.2382 USD
7 months ago
Apr 01, 2024
Sell 10.1 K USD
Thunen Shelley B
Chief Financial Officer
- 200
50.37 USD
7 months ago
Apr 01, 2024
Sell 28 K USD
Thunen Shelley B
Chief Financial Officer
- 543
51.5 USD
8 months ago
Mar 01, 2024
Sell 64.1 K USD
Thunen Shelley B
Chief Financial Officer
- 1166
54.945 USD
8 months ago
Mar 01, 2024
Sell 359 K USD
Thunen Shelley B
Chief Financial Officer
- 6361
56.3776 USD
8 months ago
Mar 01, 2024
Sell 141 K USD
Thunen Shelley B
Chief Financial Officer
- 2473
57.0327 USD
9 months ago
Feb 16, 2024
Sell 275 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
55 USD
9 months ago
Feb 15, 2024
Sell 265 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
53 USD
9 months ago
Feb 15, 2024
Sell 270 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
54 USD
9 months ago
Feb 14, 2024
Sell 260 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
52 USD
9 months ago
Feb 16, 2024
Sell 280 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
56 USD
9 months ago
Feb 14, 2024
Bought 205 K USD
Tammenoms Bakker Juliet
Director
+ 4000
51.2883 USD
9 months ago
Feb 12, 2024
Bought 202 K USD
Tammenoms Bakker Juliet
Director
+ 4000
50.3799 USD
9 months ago
Feb 09, 2024
Sell 271 K USD
Goldshleger Ilya
Chief Operating Officer
- 5365
50.5012 USD
9 months ago
Feb 09, 2024
Sell 255 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
51 USD
9 months ago
Feb 05, 2024
Sell 429 K USD
Thunen Shelley B
Chief Financial Officer
- 9125
47.0232 USD
9 months ago
Feb 06, 2024
Sell 754 K USD
Thunen Shelley B
Chief Financial Officer
- 15875
47.4692 USD
9 months ago
Feb 01, 2024
Sell 1.02 M USD
LINK WILLIAM J PHD
Director
- 20598
49.5415 USD
9 months ago
Feb 01, 2024
Sell 383 K USD
LINK WILLIAM J PHD
Director
- 7652
50.0084 USD
9 months ago
Feb 01, 2024
Sell 173 K USD
Goldshleger Ilya
Chief Operating Officer
- 3539
49 USD
9 months ago
Feb 01, 2024
Sell 148 K USD
Goldshleger Ilya
Chief Operating Officer
- 3000
49.5 USD
9 months ago
Feb 01, 2024
Sell 29.5 K USD
Goldshleger Ilya
Chief Operating Officer
- 590
50 USD
9 months ago
Feb 01, 2024
Sell 500 K USD
Weinberg Eric
Chief Commercial Officer
- 10000
50.0004 USD
9 months ago
Jan 26, 2024
Sell 1.5 M USD
Thunen Shelley B
Chief Financial Officer
- 31772
47.1077 USD
9 months ago
Jan 22, 2024
Sell 480 K USD
Weinberg Eric
Chief Commercial Officer
- 10000
48.0006 USD
9 months ago
Jan 22, 2024
Sell 240 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
48 USD
9 months ago
Jan 18, 2024
Sell 161 K USD
Maniar Shweta
Director
- 3520
45.6851 USD
9 months ago
Jan 18, 2024
Sell 132 K USD
Maniar Shweta
Director
- 2879
45.7603 USD
10 months ago
Jan 09, 2024
Sell 235 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
47 USD
10 months ago
Jan 09, 2024
Sell 460 K USD
Weinberg Eric
Chief Commercial Officer
- 10000
46 USD
10 months ago
Jan 08, 2024
Sell 420 K USD
Weinberg Eric
Chief Commercial Officer
- 10000
42 USD
10 months ago
Jan 08, 2024
Sell 700 K USD
Warner Robert Keith
Director
- 16530
42.3708 USD
10 months ago
Jan 08, 2024
Sell 314 K USD
Warner Robert Keith
Director
- 7220
43.4217 USD
10 months ago
Jan 08, 2024
Sell 289 K USD
Maniar Shweta
Director
- 6418
45 USD
10 months ago
Jan 08, 2024
Sell 1.36 M USD
Kurtz Ronald M MD
President & CEO
- 31250
43.5 USD
10 months ago
Jan 08, 2024
Sell 1.41 M USD
Kurtz Ronald M MD
President & CEO
- 31250
45.0002 USD
10 months ago
Jan 08, 2024
Sell 210 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
42 USD
10 months ago
Jan 08, 2024
Sell 215 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
43 USD
10 months ago
Jan 08, 2024
Sell 225 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
45 USD
10 months ago
Jan 08, 2024
Sell 90.1 K USD
Corley Jesse Anderson
Director
- 2000
45.0293 USD
10 months ago
Jan 02, 2024
Sell 175 K USD
Thunen Shelley B
Chief Financial Officer
- 4519
38.7677 USD
10 months ago
Jan 02, 2024
Sell 217 K USD
Thunen Shelley B
Chief Financial Officer
- 5481
39.631 USD
10 months ago
Dec 27, 2023
Sell 924 K USD
Kurtz Ronald M MD
President & CEO
- 22500
41.0888 USD
10 months ago
Dec 22, 2023
Sell 51.4 K USD
Weinberg Eric
Chief Commercial Officer
- 1285
40 USD
10 months ago
Dec 22, 2023
Sell 200 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
40 USD
11 months ago
Dec 18, 2023
Sell 36.5 K USD
Goldshleger Ilya
Chief Operating Officer
- 937
38.987 USD
11 months ago
Dec 18, 2023
Sell 191 K USD
Goldshleger Ilya
Chief Operating Officer
- 4894
38.9308 USD
11 months ago
Dec 18, 2023
Sell 4.18 K USD
Goldshleger Ilya
Chief Operating Officer
- 106
39.45 USD
11 months ago
Dec 18, 2023
Sell 195 K USD
Goldshleger Ilya
Chief Operating Officer
- 5000
39.094 USD
11 months ago
Dec 15, 2023
Sell 349 K USD
Weinberg Eric
Chief Commercial Officer
- 8715
40.0127 USD
11 months ago
Dec 15, 2023
Sell 393 K USD
Thunen Shelley B
Chief Financial Officer
- 10000
39.312 USD
11 months ago
Dec 15, 2023
Sell 393 K USD
Thunen Shelley B
Chief Financial Officer
- 10000
39.3206 USD
11 months ago
Dec 15, 2023
Sell 787 K USD
Thunen Shelley B
Chief Financial Officer
- 20000
39.3492 USD
11 months ago
Dec 14, 2023
Sell 401 K USD
Corley Jesse Anderson
Director
- 10000
40.1224 USD
11 months ago
Dec 14, 2023
Sell 80.2 K USD
Corley Jesse Anderson
Director
- 2000
40.1226 USD
11 months ago
Dec 14, 2023
Sell 800 K USD
Kurtz Ronald M MD
President & CEO
- 20000
40.0082 USD
11 months ago
Dec 14, 2023
Sell 788 K USD
Kurtz Ronald M MD
President & CEO
- 20000
39.4011 USD
11 months ago
Dec 08, 2023
Sell 508 K USD
Warner Robert Keith
Director
- 14502
35.0094 USD
11 months ago
Dec 11, 2023
Sell 193 K USD
Warner Robert Keith
Director
- 5498
35.0755 USD
11 months ago
Nov 28, 2023
Sell 4.3 M USD
Tammenoms Bakker Juliet
Director
- 145068
29.6208 USD
11 months ago
Nov 29, 2023
Sell 10.4 M USD
Tammenoms Bakker Juliet
Director
- 349245
29.7747 USD
1 year ago
Nov 14, 2023
Sell 2.71 M USD
Tammenoms Bakker Juliet
Director
- 100000
27.1259 USD
1 year ago
Nov 15, 2023
Sell 10.9 M USD
Tammenoms Bakker Juliet
Director
- 400000
27.1954 USD
1 year ago
Sep 07, 2023
Sell 601 K USD
Tammenoms Bakker Juliet
Director
- 19967
30.0988 USD
1 year ago
Sep 08, 2023
Sell 303 K USD
Tammenoms Bakker Juliet
Director
- 10033
30.2463 USD
1 year ago
Sep 11, 2023
Sell 88.5 K USD
Tammenoms Bakker Juliet
Director
- 2950
30.0084 USD
1 year ago
Aug 29, 2023
Sell 120 K USD
Maniar Shweta
Director
- 4292
28.064 USD
1 year ago
Aug 25, 2023
Sell 474 K USD
Tammenoms Bakker Juliet
Director
- 16208
29.2528 USD
1 year ago
Aug 17, 2023
Sell 556 K USD
Tammenoms Bakker Juliet
Director
- 18484
30.0635 USD
1 year ago
Aug 18, 2023
Sell 426 K USD
Tammenoms Bakker Juliet
Director
- 14651
29.0681 USD
1 year ago
Feb 10, 2023
Bought 6 M USD
Tammenoms Bakker Juliet
Director
+ 480000
12.5 USD
3 years ago
Nov 17, 2021
Bought 102 K USD
Corley Jesse Anderson
Director
+ 8150
12.485 USD
3 years ago
Aug 05, 2021
Bought 18.8 K USD
Goldshleger Ilya
Chief Operating Officer
+ 1372
13.69 USD
3 years ago
Aug 05, 2021
Bought 14.5 K USD
Goldshleger Ilya
Chief Operating Officer
+ 1000
14.4922 USD
3 years ago
Aug 05, 2021
Bought 134 USD
Weinberg Eric
Chief Commercial Officer
+ 9
14.9 USD
3 years ago
Aug 04, 2021
Bought 9.99 K USD
Weinberg Eric
Chief Commercial Officer
+ 615
16.2503 USD
3 years ago
Aug 03, 2021
Bought 17 USD
Weinberg Eric
Chief Commercial Officer
+ 1
17.029 USD
3 years ago
Aug 02, 2021
Bought 1.53 K USD
Weinberg Eric
Chief Commercial Officer
+ 90
17.0367 USD
3 years ago
Jul 30, 2021
Bought 3.56 K USD
Weinberg Eric
Chief Commercial Officer
+ 210
16.9377 USD
3 years ago
Aug 03, 2021
Bought 2 M USD
Tammenoms Bakker Juliet
Director
+ 125000
16 USD
3 years ago
Aug 03, 2021
Bought 8 M USD
Tammenoms Bakker Juliet
Director
+ 500000
16 USD
3 years ago
Aug 03, 2021
Bought 200 K USD
Tammenoms Bakker Juliet
Director
+ 12500
16 USD
3 years ago
Aug 03, 2021
Bought 1.25 M USD
Corley Jesse Anderson
Director
+ 78125
16 USD
3 years ago
Aug 03, 2021
Bought 500 K USD
LINK WILLIAM J PHD
director, 10 percent owner:
+ 31250
16 USD
3 years ago
Aug 03, 2021
Bought 500 K USD
Weinberg Eric
Chief Commercial Officer
+ 31250
16 USD
3 years ago
Aug 05, 2021
Bought 50.4 K USD
Kurtz Ronald M MD
See Remarks
+ 3638
13.8478 USD
3 years ago
Aug 03, 2021
Bought 2 M USD
Kurtz Ronald M MD
See Remarks
+ 125000
16 USD
3 years ago
Aug 03, 2021
Bought 250 K USD
Andrews Julie
Director
+ 15625
16 USD
3 years ago
Aug 03, 2021
Bought 700 K USD
Warner Robert Keith
Director
+ 43750
16 USD
7. News
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript RxSight, Inc. (NASDAQ:RXST ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Conference Call Participants Lilia Lozada - J.P. Morgan Iseult McMahon - BTIG Lei Huang - Wells Fargo Craig Bijou - Bank of America Young Li - Jefferies Tom Stephan - Stifel Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Operator Thank you for standing by. seekingalpha.com - 1 week ago
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3 RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.35 per share a year ago. zacks.com - 1 week ago
RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024 ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com - 3 weeks ago
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September. globenewswire.com - 2 months ago
Investing In The Future Of Cataract Surgery: The RxSight Advantage RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance. seekingalpha.com - 3 months ago
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect? The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 3 months ago
RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript RxSight, Inc. (NASDAQ:RXST ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Oliver Moravcevic - Vice President, Investor Relations Conference Call Participants Ryan Zimmerman - BTIG Robbie Marcus - J.P. Morgan Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Tom Stephan - Stifel Operator Good day and thank you for standing by. seekingalpha.com - 3 months ago
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2 RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.40 per share a year ago. zacks.com - 3 months ago
RxSight, Inc. Reports Second Quarter 2024 Financial Results ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024. globenewswire.com - 3 months ago
The 3 Best Med Tech Stocks to Buy Now According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments. investorplace.com - 3 months ago
Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 3 months ago
RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024 ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com - 3 months ago
8. Profile Summary

RxSight, Inc. RXST

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.82 B
Dividend Yield 0.00%
Description RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Contact 100 Columbia, Aliso Viejo, CA, 92656 https://www.rxsight.com
IPO Date July 30, 2021
Employees 374
Officers Ms. Shelley B. Thunen Co-President & Chief Financial Officer Dr. Ilya Goldshleger Ph.D. Co-President & Chief Operating Officer Mr. Steve Everly Senior Vice President of Sales of North America Mr. Matt Haller Ph.D. Chief Technology Officer Mr. Oliver Moravcevic Vice President of Investor Relations Mr. Roy Freeman Senior Vice President of Marketing & Professional Relations Ms. Rebecca Williston Vice President of Accounting & Finance Ms. Caroline Vaughn Vice President of Human Resources Mr. Eric J. Weinberg Co-President & Chief Commercial Officer Dr. Ronald M. Kurtz M.D. President, Chief Executive Officer & Director